Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics' stock has experienced significant volatility and decline over the past six months. Key events include a positive movement in December 2025, the announcement of the Tome skincare line in March 2026, the appointment of a new VP of Marketing, a corporate update and financial results report, and the acceptance of an Australian patent application in April 2026. Maxim Group maintained a Buy rating but cut the target price, Bigger Capital updated their Schedule 13G/A filing, and RBC Capital initiated coverage with an outperform rating and a price target of $40.00. Shares of Dermata Therapeutics underwent a 1-15 reverse stock split.

There is no readily available information indicating demand seasonality for Dermata Therapeutics, Inc.'s products and services.

Dermata Therapeutics, Inc. has shifted from pharmaceutical development to direct-to-consumer skincare solutions under the brand Tome. Previously focused on pharmaceutical product candidates like XYNGARI and DMT410, the company is now developing a skin renewal product called the Foundational Treatment and a once-weekly acne treatment system, both intended for direct consumer and in-office sales.

Dermata Therapeutics is headquartered in San Diego, California. The company has an international intellectual property presence with an accepted Australian patent application for topical application of dermal fillers using its Bioneedle Delivery System.

Dermata Therapeutics has strategically repositioned itself to focus on direct-to-consumer skincare, launching the Tome brand in March 2026. The company aims to build a reputation for high-quality, scientifically proven OTC pharmaceutical products that empower consumers to manage their skin health independently.

Institutional investors own 8.67% of Dermata Therapeutics' stock, with 11 institutional owners holding 81,263 shares. Major institutional owners include UBS Group AG, Welch & Forbes Llc, and Clear Street Group Inc. Key individual owners include Gerald T. Proehl, Kyri K. Van Hoose, and Bigger Capital Funds, LP.